Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 41

1.

53BP1 as a potential predictor of response in PARP inhibitor-treated homologous recombination-deficient ovarian cancer.

Hurley RM, Wahner Hendrickson AE, Visscher DW, Ansell P, Harrell MI, Wagner JM, Negron V, Goergen KM, Maurer MJ, Oberg AL, Meng XW, Flatten KS, De Jonge MJA, Van Herpen CD, Gietema JA, Koornstra RHT, Jager A, den Hollander MW, Dudley M, Shepherd SP, Swisher EM, Kaufmann SH.

Gynecol Oncol. 2019 Apr;153(1):127-134. doi: 10.1016/j.ygyno.2019.01.015. Epub 2019 Jan 25.

PMID:
30686551
2.

BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma.

Lin KK, Harrell MI, Oza AM, Oaknin A, Ray-Coquard I, Tinker AV, Helman E, Radke MR, Say C, Vo LT, Mann E, Isaacson JD, Maloney L, O'Malley DM, Chambers SK, Kaufmann SH, Scott CL, Konecny GE, Coleman RL, Sun JX, Giordano H, Brenton JD, Harding TC, McNeish IA, Swisher EM.

Cancer Discov. 2019 Feb;9(2):210-219. doi: 10.1158/2159-8290.CD-18-0715. Epub 2018 Nov 13.

PMID:
30425037
3.

Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma.

Kondrashova O, Topp M, Nesic K, Lieschke E, Ho GY, Harrell MI, Zapparoli GV, Hadley A, Holian R, Boehm E, Heong V, Sanij E, Pearson RB, Krais JJ, Johnson N, McNally O, Ananda S, Alsop K, Hutt KJ, Kaufmann SH, Lin KK, Harding TC, Traficante N; Australian Ovarian Cancer Study (AOCS), deFazio A, McNeish IA, Bowtell DD, Swisher EM, Dobrovic A, Wakefield MJ, Scott CL.

Nat Commun. 2018 Sep 28;9(1):3970. doi: 10.1038/s41467-018-05564-z.

4.

Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance.

Pettitt SJ, Krastev DB, Brandsma I, Dréan A, Song F, Aleksandrov R, Harrell MI, Menon M, Brough R, Campbell J, Frankum J, Ranes M, Pemberton HN, Rafiq R, Fenwick K, Swain A, Guettler S, Lee JM, Swisher EM, Stoynov S, Yusa K, Ashworth A, Lord CJ.

Nat Commun. 2018 May 10;9(1):1849. doi: 10.1038/s41467-018-03917-2.

5.

Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 study.

Lee JM, Nair J, Zimmer A, Lipkowitz S, Annunziata CM, Merino MJ, Swisher EM, Harrell MI, Trepel JB, Lee MJ, Bagheri MH, Botesteanu DA, Steinberg SM, Minasian L, Ekwede I, Kohn EC.

Lancet Oncol. 2018 Feb;19(2):207-215. doi: 10.1016/S1470-2045(18)30009-3. Epub 2018 Jan 18.

PMID:
29361470
6.

Clinical characteristics and outcomes of patients with BRCA1 or RAD51C methylated versus mutated ovarian carcinoma.

Bernards SS, Pennington KP, Harrell MI, Agnew KJ, Garcia RL, Norquist BM, Swisher EM.

Gynecol Oncol. 2018 Feb;148(2):281-285. doi: 10.1016/j.ygyno.2017.12.004. Epub 2017 Dec 9.

PMID:
29233532
7.

Mutations in Homologous Recombination Genes and Outcomes in Ovarian Carcinoma Patients in GOG 218: An NRG Oncology/Gynecologic Oncology Group Study.

Norquist BM, Brady MF, Harrell MI, Walsh T, Lee MK, Gulsuner S, Bernards SS, Casadei S, Burger RA, Tewari KS, Backes F, Mannel RS, Glaser G, Bailey C, Rubin S, Soper J, Lankes HA, Ramirez NC, King MC, Birrer MJ, Swisher EM.

Clin Cancer Res. 2018 Feb 15;24(4):777-783. doi: 10.1158/1078-0432.CCR-17-1327. Epub 2017 Nov 30.

8.

A Phase I Clinical Trial of the Poly(ADP-ribose) Polymerase Inhibitor Veliparib and Weekly Topotecan in Patients with Solid Tumors.

Wahner Hendrickson AE, Menefee ME, Hartmann LC, Long HJ, Northfelt DW, Reid JM, Boakye-Agyeman F, Kayode O, Flatten KS, Harrell MI, Swisher EM, Poirer GG, Satele D, Allred J, Lensing JL, Chen A, Ji J, Zang Y, Erlichman C, Haluska P, Kaufmann SH.

Clin Cancer Res. 2018 Feb 15;24(4):744-752. doi: 10.1158/1078-0432.CCR-17-1590. Epub 2017 Nov 14.

9.

Phase I/Ib study of olaparib and carboplatin in women with triple negative breast cancer.

Lee JM, Hays JL, Chiou VL, Annunziata CM, Swisher EM, Harrell MI, Yu M, Gordon N, Sissung TM, Ji J, Figg WD, Minasian L, Lipkowitz S, Wood BJ, Doroshow J, Kohn EC.

Oncotarget. 2017 Mar 25;8(45):79175-79187. doi: 10.18632/oncotarget.16577. eCollection 2017 Oct 3.

10.

Exploring the Pregnant Guinea Pig as a Model for Group B Streptococcus Intrauterine Infection.

Harrell MI, Burnside K, Whidbey C, Vornhagen J, Adams Waldorf KM, Rajagopal L.

J Infect Dis Med. 2017 Sep;2(2). pii: 109. Epub 2017 Jul 27.

11.

Tumor Regulation of Lymph Node Lymphatic Sinus Growth and Lymph Flow in Mice and in Humans.

Habenicht LM, Kirschbaum SB, Furuya M, Harrell MI, Ruddell A.

Yale J Biol Med. 2017 Sep 25;90(3):403-415. eCollection 2017 Sep. Review.

12.

Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma.

Kondrashova O, Nguyen M, Shield-Artin K, Tinker AV, Teng NNH, Harrell MI, Kuiper MJ, Ho GY, Barker H, Jasin M, Prakash R, Kass EM, Sullivan MR, Brunette GJ, Bernstein KA, Coleman RL, Floquet A, Friedlander M, Kichenadasse G, O'Malley DM, Oza A, Sun J, Robillard L, Maloney L, Bowtell D, Giordano H, Wakefield MJ, Kaufmann SH, Simmons AD, Harding TC, Raponi M, McNeish IA, Swisher EM, Lin KK, Scott CL; AOCS Study Group.

Cancer Discov. 2017 Sep;7(9):984-998. doi: 10.1158/2159-8290.CD-17-0419. Epub 2017 Jun 6.

13.

Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I Study.

Lee JM, Cimino-Mathews A, Peer CJ, Zimmer A, Lipkowitz S, Annunziata CM, Cao L, Harrell MI, Swisher EM, Houston N, Botesteanu DA, Taube JM, Thompson E, Ogurtsova A, Xu H, Nguyen J, Ho TW, Figg WD, Kohn EC.

J Clin Oncol. 2017 Jul 1;35(19):2193-2202. doi: 10.1200/JCO.2016.72.1340. Epub 2017 May 4.

14.

Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.

Swisher EM, Lin KK, Oza AM, Scott CL, Giordano H, Sun J, Konecny GE, Coleman RL, Tinker AV, O'Malley DM, Kristeleit RS, Ma L, Bell-McGuinn KM, Brenton JD, Cragun JM, Oaknin A, Ray-Coquard I, Harrell MI, Mann E, Kaufmann SH, Floquet A, Leary A, Harding TC, Goble S, Maloney L, Isaacson J, Allen AR, Rolfe L, Yelensky R, Raponi M, McNeish IA.

Lancet Oncol. 2017 Jan;18(1):75-87. doi: 10.1016/S1470-2045(16)30559-9. Epub 2016 Nov 29.

15.

In vivo anti-tumor activity of the PARP inhibitor niraparib in homologous recombination deficient and proficient ovarian carcinoma.

AlHilli MM, Becker MA, Weroha SJ, Flatten KS, Hurley RM, Harrell MI, Oberg AL, Maurer MJ, Hawthorne KM, Hou X, Harrington SC, McKinstry S, Meng XW, Wilcoxen KM, Kalli KR, Swisher EM, Kaufmann SH, Haluska P.

Gynecol Oncol. 2016 Nov;143(2):379-388. doi: 10.1016/j.ygyno.2016.08.328. Epub 2016 Sep 8.

16.

Neoplastic cellularity is associated with clinical and molecular features of high-grade serous ovarian carcinoma.

Morse CB, Norquist BM, Harrell MI, Agnew KJ, Gray HJ, Urban RR, Garcia RL, Goff BA, Swisher EM.

Gynecol Oncol. 2016 Nov;143(2):389-392. doi: 10.1016/j.ygyno.2016.08.324. Epub 2016 Aug 27.

PMID:
27575909
17.

RING domain-deficient BRCA1 promotes PARP inhibitor and platinum resistance.

Wang Y, Krais JJ, Bernhardy AJ, Nicolas E, Cai KQ, Harrell MI, Kim HH, George E, Swisher EM, Simpkins F, Johnson N.

J Clin Invest. 2016 Aug 1;126(8):3145-57. doi: 10.1172/JCI87033. Epub 2016 Jul 25.

18.

The BRCA1-Δ11q Alternative Splice Isoform Bypasses Germline Mutations and Promotes Therapeutic Resistance to PARP Inhibition and Cisplatin.

Wang Y, Bernhardy AJ, Cruz C, Krais JJ, Nacson J, Nicolas E, Peri S, van der Gulden H, van der Heijden I, O'Brien SW, Zhang Y, Harrell MI, Johnson SF, Candido Dos Reis FJ, Pharoah PD, Karlan B, Gourley C, Lambrechts D, Chenevix-Trench G, Olsson H, Benitez JJ, Greene MH, Gore M, Nussbaum R, Sadetzki S, Gayther SA, Kjaer SK; kConFab Investigators, D'Andrea AD, Shapiro GI, Wiest DL, Connolly DC, Daly MB, Swisher EM, Bouwman P, Jonkers J, Balmaña J, Serra V, Johnson N.

Cancer Res. 2016 May 1;76(9):2778-90. doi: 10.1158/0008-5472.CAN-16-0186.

19.

Ultra-deep sequencing detects ovarian cancer cells in peritoneal fluid and reveals somatic TP53 mutations in noncancerous tissues.

Krimmel JD, Schmitt MW, Harrell MI, Agnew KJ, Kennedy SR, Emond MJ, Loeb LA, Swisher EM, Risques RA.

Proc Natl Acad Sci U S A. 2016 May 24;113(21):6005-10. doi: 10.1073/pnas.1601311113. Epub 2016 May 5.

20.

Poly (ADP-Ribose) Polymerase Inhibitor Hypersensitivity in Aggressive Myeloproliferative Neoplasms.

Pratz KW, Koh BD, Patel AG, Flatten KS, Poh W, Herman JG, Dilley R, Harrell MI, Smith BD, Karp JE, Swisher EM, McDevitt MA, Kaufmann SH.

Clin Cancer Res. 2016 Aug 1;22(15):3894-902. doi: 10.1158/1078-0432.CCR-15-2351. Epub 2016 Mar 15.

21.

A Hyperhemolytic/Hyperpigmented Group B Streptococcus Strain with a CovR Mutation Isolated from an Adolescent Patient with Sore Throat.

Whidbey C, Burnside K, Martinez RM, Gendrin C, Vornhagen J, Frando A, Harrell MI, McAdams R, Rajagopal L.

Clin Res Infect Dis. 2015;2(2). pii: 1018. Epub 2015 Sep 3.

22.

Somatic Mosaic Mutations in PPM1D and TP53 in the Blood of Women With Ovarian Carcinoma.

Swisher EM, Harrell MI, Norquist BM, Walsh T, Brady M, Lee M, Hershberg R, Kalli KR, Lankes H, Konnick EQ, Pritchard CC, Monk BJ, Chan JK, Burger R, Kaufmann SH, Birrer MJ.

JAMA Oncol. 2016 Mar;2(3):370-2. doi: 10.1001/jamaoncol.2015.6053.

23.

Inherited Mutations in Women With Ovarian Carcinoma.

Norquist BM, Harrell MI, Brady MF, Walsh T, Lee MK, Gulsuner S, Bernards SS, Casadei S, Yi Q, Burger RA, Chan JK, Davidson SA, Mannel RS, DiSilvestro PA, Lankes HA, Ramirez NC, King MC, Swisher EM, Birrer MJ.

JAMA Oncol. 2016 Apr;2(4):482-90. doi: 10.1001/jamaoncol.2015.5495.

24.

Genetic characterization of early onset ovarian carcinoma.

Bernards SS, Norquist BM, Harrell MI, Agnew KJ, Lee MK, Walsh T, Swisher EM.

Gynecol Oncol. 2016 Feb;140(2):221-5. doi: 10.1016/j.ygyno.2015.12.017. Epub 2015 Dec 21.

25.

Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas.

Pennington KP, Walsh T, Harrell MI, Lee MK, Pennil CC, Rendi MH, Thornton A, Norquist BM, Casadei S, Nord AS, Agnew KJ, Pritchard CC, Scroggins S, Garcia RL, King MC, Swisher EM.

Clin Cancer Res. 2014 Feb 1;20(3):764-75. doi: 10.1158/1078-0432.CCR-13-2287. Epub 2013 Nov 15.

26.

Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance.

Johnson N, Johnson SF, Yao W, Li YC, Choi YE, Bernhardy AJ, Wang Y, Capelletti M, Sarosiek KA, Moreau LA, Chowdhury D, Wickramanayake A, Harrell MI, Liu JF, D'Andrea AD, Miron A, Swisher EM, Shapiro GI.

Proc Natl Acad Sci U S A. 2013 Oct 15;110(42):17041-6. doi: 10.1073/pnas.1305170110. Epub 2013 Oct 1.

27.

A hemolytic pigment of Group B Streptococcus allows bacterial penetration of human placenta.

Whidbey C, Harrell MI, Burnside K, Ngo L, Becraft AK, Iyer LM, Aravind L, Hitti J, Adams Waldorf KM, Rajagopal L.

J Exp Med. 2013 Jun 3;210(6):1265-81. doi: 10.1084/jem.20122753. Epub 2013 May 27.

28.

Characteristics of women with ovarian carcinoma who have BRCA1 and BRCA2 mutations not identified by clinical testing.

Norquist BM, Pennington KP, Agnew KJ, Harrell MI, Pennil CC, Lee MK, Casadei S, Thornton AM, Garcia RL, Walsh T, Swisher EM.

Gynecol Oncol. 2013 Mar;128(3):483-7. doi: 10.1016/j.ygyno.2012.12.015. Epub 2012 Dec 19.

29.

Vaccination with a UV-irradiated genetically attenuated mutant of Staphylococcus aureus provides protection against subsequent systemic infection.

Burnside K, Lembo A, Harrell MI, Klein JA, Lopez-Guisa J, Siegesmund AM, Torgerson TR, Oukka M, Molina DM, Rajagopal L.

J Infect Dis. 2012 Dec 1;206(11):1734-44. doi: 10.1093/infdis/jis579. Epub 2012 Sep 10.

30.

The fragmented mitochondrial ribosomal RNAs of Plasmodium falciparum.

Feagin JE, Harrell MI, Lee JC, Coe KJ, Sands BH, Cannone JJ, Tami G, Schnare MN, Gutell RR.

PLoS One. 2012;7(6):e38320. doi: 10.1371/journal.pone.0038320. Epub 2012 Jun 22.

31.

Serine/threonine phosphatase Stp1 mediates post-transcriptional regulation of hemolysin, autolysis, and virulence of group B Streptococcus.

Burnside K, Lembo A, Harrell MI, Gurney M, Xue L, BinhTran NT, Connelly JE, Jewell KA, Schmidt BZ, de los Reyes M, Tao WA, Doran KS, Rajagopal L.

J Biol Chem. 2011 Dec 23;286(51):44197-210. doi: 10.1074/jbc.M111.313486. Epub 2011 Nov 11.

32.

B lymphocytes promote lymphogenous metastasis of lymphoma and melanoma.

Ruddell A, Harrell MI, Furuya M, Kirschbaum SB, Iritani BM.

Neoplasia. 2011 Aug;13(8):748-57.

33.

Dynamic contrast-enhanced magnetic resonance imaging of tumor-induced lymph flow.

Ruddell A, Harrell MI, Minoshima S, Maravilla KR, Iritani BM, White SW, Partridge SC.

Neoplasia. 2008 Jul;10(7):706-13, 1 p following 713.

34.

The enduring hypoxic response of Mycobacterium tuberculosis.

Rustad TR, Harrell MI, Liao R, Sherman DR.

PLoS One. 2008 Jan 30;3(1):e1502. doi: 10.1371/journal.pone.0001502.

35.

Lymph node mapping in the mouse.

Harrell MI, Iritani BM, Ruddell A.

J Immunol Methods. 2008 Mar 20;332(1-2):170-4. doi: 10.1016/j.jim.2007.11.012. Epub 2007 Dec 18.

36.
37.

Inhibition of respiration by nitric oxide induces a Mycobacterium tuberculosis dormancy program.

Voskuil MI, Schnappinger D, Visconti KC, Harrell MI, Dolganov GM, Sherman DR, Schoolnik GK.

J Exp Med. 2003 Sep 1;198(5):705-13.

38.

Rv3133c/dosR is a transcription factor that mediates the hypoxic response of Mycobacterium tuberculosis.

Park HD, Guinn KM, Harrell MI, Liao R, Voskuil MI, Tompa M, Schoolnik GK, Sherman DR.

Mol Microbiol. 2003 May;48(3):833-43.

39.

Regulation of the Mycobacterium tuberculosis hypoxic response gene encoding alpha -crystallin.

Sherman DR, Voskuil M, Schnappinger D, Liao R, Harrell MI, Schoolnik GK.

Proc Natl Acad Sci U S A. 2001 Jun 19;98(13):7534-9. Erratum in: Proc Natl Acad Sci U S A 2001 Dec 18;98(26):15393.

40.

Peptidomimetic inhibitors of protein farnesyltransferase show potent antimalarial activity.

Ohkanda J, Lockman JW, Yokoyama K, Gelb MH, Croft SL, Kendrick H, Harrell MI, Feagin JE, Blaskovich MA, Sebti SM, Hamilton AD.

Bioorg Med Chem Lett. 2001 Mar 26;11(6):761-4.

PMID:
11277514
41.

Transcriptional mapping and RNA processing of the Plasmodium falciparum mitochondrial mRNAs.

Rehkopf DH, Gillespie DE, Harrell MI, Feagin JE.

Mol Biochem Parasitol. 2000 Jan 5;105(1):91-103.

PMID:
10613702

Supplemental Content

Loading ...
Support Center